Back To Search Instructions
Protocols
11 protocols meet the specified criteria
Phase: 1
Protocol No.TitleStatus
1300000725A Cardiac Safety Study of TH-302 in Patients with Advanced Solid TumorsNot Open
1502661845A Phase 1 Study of Stereotactic Body Radiotherapy (SBRT) for the treatment of multiple Metastases (NRG-BR001)Open
1601304634A Phase 1a/1b Multicenter, Single-Arm, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Preliminary Activity of Oral ACY-241 Alone and in Combination With Pomalidomide and Low-Dose Dexamethasone in Patients With Relapsed or Relapsed-and-Refractory Multiple MyelomaOpen
1602381312A PHASE 1A/B STUDY OF THE FOLIC ACID-TUBULYSIN CONJUGATE EC1456 IN PATIENTS WITH ADVANCED SOLID TUMORSOpen
1603472947Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Dose Regimens of MT-3724 for the Treatment of Patients with Relapsed Chronic B-cell Lymphocytic Leukemia or Small Lymphocytic LymphomaOpen
1604536433A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose- Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable CancersOpen
1606616633Phase Ib Trial of Pembrolizumab (MK-3475) in Combination with Dinaciclib (MK-7965) in Subjects with Hematologic Malignancies (KEYNOTE-155)Open
1607750114A Phase 1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of the Combination of JNJ-64052781 with Ibrutinib in Subjects with B-Cell MalignanciesNot Open
1608779834A FIRST-IN-HUMAN STUDY OF REPEAT DOSING WITH REGN2810, A MONOCLONAL, FULLY HUMAN ANTIBODY TO PROGRAMMED DEATH - 1 (PD-1), AS SINGLE THERAPY AND IN COMBINATION WITH OTHER ANTI-CANCER THERAPIES, IN PATIENTS WITH ADVANCED MALIGNANCIESOpen
1608796654A Phase 1 Study of LY2801653 in Patients with Advanced CancerOpen
1609875338A Phase 1 Dose Escalation Study To Evaluate The Safety, Pharmacokinetics And Pharmacodynamics Of Intravenous PF-06747143, Administered As Single Agent Or In Combination With Standard Chemotherapy In Adult Patients With Acute Myeloid LeukemiaOpen